Novel Antisense Technology for Treating Epidermolysis Bullosa Simplex (Clinical Fellowship)

Project Details

StatusFinished
Effective start/end date1/10/153/01/23

Funding

  • (McLean 13): £130,779.00
  • (McLean 13): £23,000.00
  • (McLean 13): £119,823.00
  • (McLean 13 Year 3): £148,840.61
  • (Steensel/Mclean 1): £82,258.00